Department of Neurology, Tokyo Women's Medical University Hospital.
J Atheroscler Thromb. 2022 Sep 1;29(9):1393-1408. doi: 10.5551/jat.63189. Epub 2021 Nov 12.
We aimed to determine the characteristics and vascular outcomes of stroke in renal transplant (RT) recipients and compare them with those in patients on hemodialysis (HD) and those with no renal replacement therapy (RRT).
In this prospective observational study, 717 patients (mean age, 70.8 years; male, 60.5%) with acute ischemic stroke within one week of onset were consecutively enrolled and followed for one year. The patients were classified into three groups: (1) living donor RT recipients (n=27); (2) patients on maintenance HD before the index stroke (n=39); and (3) those with no history of RRT (n=651). The primary outcome was a composite of major adverse cardiovascular events (MACE).
Diabetic nephropathy was the most common reason for RRT in both RT and HD patients. RT patients were more likely to have embolic stroke of undetermined source (33.3%) than others, whereas HD patients more often had cardioembolism (51.3%). No difference was observed in the MACE risk between the patients in RT and non-RRT groups (annual rate, 11.3% vs. 13.1%; log-rank P=0.82; hazard ratio [95% confidence interval], 0.92 [0.29-2.98]). In contrast, HD patients had a greater risk of MACE than those with no RRT (annual rate, 28.2% vs. 13.1%; log-rank P=0.019; hazard ratio [95% confidence interval], 2.24 [1.16-4.3]).
The underlying etiologies of stroke differed in RT and HD patients. The one-year risk of MACE for stroke patients who had received an RT was lower than that for patients undergoing HD and comparable with that of patients with no RRT.
本研究旨在明确肾移植(RT)受者发生卒中的特点和血管结局,并与血液透析(HD)患者和无肾脏替代治疗(RRT)患者进行比较。
本前瞻性观察性研究连续纳入了 717 例发病后 1 周内发生急性缺血性卒中的患者(平均年龄 70.8 岁,男性占 60.5%),并对其进行为期 1 年的随访。将患者分为三组:(1)活体供肾 RT 受者(n=27);(2)发生卒中前接受维持性 HD 治疗的患者(n=39);(3)无 RRT 治疗史的患者(n=651)。主要终点事件为主要不良心血管事件(MACE)的复合终点。
RT 和 HD 患者接受 RRT 的主要原因均为糖尿病肾病。与其他两组相比,RT 患者中不明来源的栓塞性卒中更为常见(33.3%),而 HD 患者中更常发生心源性栓塞(51.3%)。RT 组和非 RRT 组患者的 MACE 风险无差异(年发生率分别为 11.3%和 13.1%;log-rank P=0.82;风险比[95%置信区间],0.92[0.29-2.98])。相比之下,HD 患者的 MACE 发生率高于无 RRT 治疗的患者(年发生率分别为 28.2%和 13.1%;log-rank P=0.019;风险比[95%置信区间],2.24[1.16-4.3])。
RT 和 HD 患者卒中的潜在病因不同。接受 RT 的卒中患者 1 年时发生 MACE 的风险低于接受 HD 治疗的患者,与无 RRT 治疗的患者相当。